Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Urogen Pharma (URGN : NSDQ)
 
 • Company Description   
UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.

Number of Employees: 235

 
 • Price / Volume Information   
Yesterday's Closing Price: $14.64 Daily Weekly Monthly
20 Day Moving Average: 3,080,873 shares
Shares Outstanding: 46.11 (millions)
Market Capitalization: $675.01 (millions)
Beta: 1.02
52 Week High: $18.15
52 Week Low: $3.42
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 32.13% 27.18%
12 Week 51.40% 27.34%
Year To Date 37.47% 28.74%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
400 Alexander Park Drive
-
Princeton,NJ 08540
USA
ph: 646-768-9780
fax: -
vincent.perrone@urogen.com http://www.urogen.com
 
 • General Corporate Information   
Officers
Elizabeth Barrett - Chief Executive Officer and President
Arie Belldegrun - Chairman
Chris Degnan - Chief Financial Officer
Cynthia Butitta - Director
Leana S. Wen - Director

Peer Information
Urogen Pharma (CORR.)
Urogen Pharma (RSPI)
Urogen Pharma (CGXP)
Urogen Pharma (BGEN)
Urogen Pharma (GTBP)
Urogen Pharma (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: M96088105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 46.11
Most Recent Split Date: (:1)
Beta: 1.02
Market Capitalization: $675.01 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.74 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.88 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 7.35
EPS Growth
vs. Year Ago Period: 5.15%
vs. Previous Quarter: -15.00%
Sales Growth
vs. Year Ago Period: 7.84%
vs. Previous Quarter: -17.55%
ROE
06/30/25 - -
03/31/25 - -97,487.15
12/31/24 - -7,363.55
ROA
06/30/25 - -
03/31/25 - -49.57
12/31/24 - -47.43
Current Ratio
06/30/25 - -
03/31/25 - 5.65
12/31/24 - 6.01
Quick Ratio
06/30/25 - -
03/31/25 - 5.47
12/31/24 - 5.81
Operating Margin
06/30/25 - -
03/31/25 - -150.68
12/31/24 - -140.35
Net Margin
06/30/25 - -
03/31/25 - -150.68
12/31/24 - -140.35
Pre-Tax Margin
06/30/25 - -
03/31/25 - -147.23
12/31/24 - -137.22
Book Value
06/30/25 - -
03/31/25 - -1.01
12/31/24 - -0.21
Inventory Turnover
06/30/25 - -
03/31/25 - 1.19
12/31/24 - 1.13
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©